SCHEMBL20119296

SCHEMBL20119296

CN1CCc2cc(NC(=O)NS(=O)(=O)C3(C)CC3)ccc2C1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA1 Q09470 8/20 0.49
KCNAB1 Q14722 8/20 0.49
ROCK2 O75116 3/20 0.42
POLB P06746 3/20 0.41
NPC1 O15118 2/20 0.41
RAB9A P51151 2/20 0.41
CA12 O43570 1/20 0.41
CA1 P00915 1/20 0.41
CA2 P00918 1/20 0.41
CA9 Q16790 1/20 0.41
DRD2 P14416 2/20 0.40
HTR2A P28223 2/20 0.40
HTR2C P28335 2/20 0.40
DRD3 P35462 2/20 0.40
HTR6 P50406 2/20 0.40
CYP1A2 P05177 1/20 0.40
CYP3A4 P08684 1/20 0.40
CYP2D6 P10635 1/20 0.40
CYP2C9 P11712 1/20 0.40
CYP2C19 P33261 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20173801 0.86 KCNA1 (0.47) KCNA1KCNAB1POLBNPC1RAB9A
SCHEMBL20119182 0.81 HDAC6 (0.46)
SCHEMBL20119483 0.80 DRD1 (0.46) CA1CA2CA9DRD2DRD3
SCHEMBL3652815 0.76 NPC1 (0.49) KCNA1KCNAB1POLBNPC1RAB9A
SCHEMBL20119168 0.75 TMPRSS2 (0.50) ROCK2DRD3CYP3A4
SCHEMBL4752371 0.74 CLK2 (0.42) ROCK2POLBNPC1RAB9ADRD2
SCHEMBL8130701 0.73 NPC1 (0.65) ROCK2POLBNPC1RAB9ACYP1A2
SCHEMBL2248318 0.72 ACLY (0.53) ROCK2NPC1RAB9AHTR2AHTR2C
SCHEMBL13347344 0.72 ALDH1A1 (0.50) NPC1RAB9ACYP1A2CYP3A4CYP2D6
SCHEMBL8131703 0.72 RAB9A (0.66) ROCK2POLBNPC1RAB9ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof ENANTA PHARMACEUTICALS, INC. (US) 2020-03-24 US disclosed
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. 2018-05-24 US disclosed
WO-2018081285-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF ENANTA PHARMACEUTICALS, INC. (US) 2018-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180141941-A1 UREA-CONTAINING ISOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF NR1H4, FXR1, SLC10A1 KCNA1 4240/4885KCNAB1 4190/4885ROCK2 4009/4885
US-10597391-B2 Urea-containing isoxazole derivatives as FXR agonists and methods of use thereof NR1H4, FXR1, SLC10A1 KCNA1 4240/4885KCNAB1 4190/4885ROCK2 4009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.